Updates are available Correction dated 2026-04-10
Click to view Correction: https://doi.org/10.1038/s41389-026-00616-2
-
Authors
Irvine, Mal
Stewart, Ashleigh
Pedersen, Bernadette
Boyd, Suzanah
Kefford, Richard
Rizos, Helen https://orcid.org/0000-0002-2094-9198
- License Information
-
More Information
Article History
Received: 17 January 2018
Revised: 26 July 2018
Accepted: 30 July 2018
First Online: 20 September 2018
Change Date: 10 April 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41389-026-00616-2
Conflict of interest
: Richard F. Kefford is on the advisory boards for BMS and Merck, makers of pembrolizumab, nivolumab and ipilimumab. The remaining authors declare that they have no conflict of interest.
